Maate-G 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination of these agents provides complementary mechanisms of action, resulting in better glycemic control than either agent alone. Maate-G 2 Tablet PR is particularly useful in patients inadequately controlled on diet and exercise alone or those who have failed monotherapy with either component. It is recommended to be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose, renal function, and liver enzymes is essential during therapy. Hypoglycemia is a potential adverse effect, primarily due to Glimepiride, and patients should be educated on recognizing and managing low blood sugar episodes. This combination therapy should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring.